Efficacy and Safety of Nucleoside Antiviral Therapy for Hepatitis B Virus-associated Cirrhosis
Author(s): QIU Qiang, XUE Rong, CHANG Jiabao, Dept. of Liver Diseases, Jiangsu Sihong County Fenjinting Hospital, Dept. of Liver Disease, Nanjing Second Hospital
Pages: 506-509
Year: 2015 Issue: 4
Journal: Evaluation and Analysis of Drug-Use in Hospital of China
Keyword: Nucleoside antiviral therapy; Hepatitis B virus-associated cirrhosis; Short-term efficacy; Safety;
Abstract: OBJECTIVE: To evaluate the short-term efficacy and safety of nucleoside antiviral therapy for hepatitis B virus-associated cirrhosis. METHODS: 50 patients with liver cirrhosis treated in hospital from January 2009 to January 2011 were assigned to receive routine therapy( control group); another 100 patients with hepatitis B virusassociated cirrhosis( observation group) treated in our hospital from January 2011 to January 2013 were assigned to receive lamivudine( subgroup A),adefovir( subgroup B) or entecavir( subgroup C). Four groups were observed and compared before and after treatment with regard to liver function [alanine aminotransferase( ALT), aspartate aminotransferase( AST),total bilirubin( TBIL),albumin( ALB) ],prothrombin time activity( PTA),liver fibrosis[hyaluronic acid( HA),laminin( LN),Ⅲ procollagen( PC-Ⅲ),Ⅳ collagen( Ⅳ-C) ],HBV-DNA negative rate and HBe Ag seroconversion rate. RESULTS: After treatment,the liver function and liver fibrosis in all of the four groups improved significantly,much as in three subgroups( group A,B and C),showing statistically significant differences between the observation group( three subgroups) and the control group( P < 0. 05),yet the differences among the three subgroups were not statistically significant( P > 0. 05); HBV-DNA negative rate and HBe Ag seroconversion rates in three subgroups were significantly higher than in the control group after treatment and the differences were statistically significant( P < 0. 05),yet the differences were not statistically significant among threesubgroups( P > 0. 05). The cost-effectiveness analysis on the three subgroups showed that subgroup C took the lead in C / E value( 2538. 0),showing statistically significant differences as compared with the other two subgroups( P <0. 05). The three subgroups in the observation group presented with only mild adverse drug reactions such as myalgia and mild fatigue. CONCLUSION: Nucleoside antiviral therapy is safe and effective for patients with hepatitis B virusassociated cirrhosis in that which can effectively improve patients’ liver function and prevent liver fibrosis; entecavir can be used as the preferred choice economically,and which is worthy of popularization in clinical application.
Pages: 506-509
Year: 2015 Issue: 4
Journal: Evaluation and Analysis of Drug-Use in Hospital of China
Keyword: Nucleoside antiviral therapy; Hepatitis B virus-associated cirrhosis; Short-term efficacy; Safety;
Abstract: OBJECTIVE: To evaluate the short-term efficacy and safety of nucleoside antiviral therapy for hepatitis B virus-associated cirrhosis. METHODS: 50 patients with liver cirrhosis treated in hospital from January 2009 to January 2011 were assigned to receive routine therapy( control group); another 100 patients with hepatitis B virusassociated cirrhosis( observation group) treated in our hospital from January 2011 to January 2013 were assigned to receive lamivudine( subgroup A),adefovir( subgroup B) or entecavir( subgroup C). Four groups were observed and compared before and after treatment with regard to liver function [alanine aminotransferase( ALT), aspartate aminotransferase( AST),total bilirubin( TBIL),albumin( ALB) ],prothrombin time activity( PTA),liver fibrosis[hyaluronic acid( HA),laminin( LN),Ⅲ procollagen( PC-Ⅲ),Ⅳ collagen( Ⅳ-C) ],HBV-DNA negative rate and HBe Ag seroconversion rate. RESULTS: After treatment,the liver function and liver fibrosis in all of the four groups improved significantly,much as in three subgroups( group A,B and C),showing statistically significant differences between the observation group( three subgroups) and the control group( P < 0. 05),yet the differences among the three subgroups were not statistically significant( P > 0. 05); HBV-DNA negative rate and HBe Ag seroconversion rates in three subgroups were significantly higher than in the control group after treatment and the differences were statistically significant( P < 0. 05),yet the differences were not statistically significant among threesubgroups( P > 0. 05). The cost-effectiveness analysis on the three subgroups showed that subgroup C took the lead in C / E value( 2538. 0),showing statistically significant differences as compared with the other two subgroups( P <0. 05). The three subgroups in the observation group presented with only mild adverse drug reactions such as myalgia and mild fatigue. CONCLUSION: Nucleoside antiviral therapy is safe and effective for patients with hepatitis B virusassociated cirrhosis in that which can effectively improve patients’ liver function and prevent liver fibrosis; entecavir can be used as the preferred choice economically,and which is worthy of popularization in clinical application.
Related Articles